登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Lancet，5月25日，Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-05-26

  • Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study

    Qilin Li 1

    Xiuli Ding 1

    Geqing Xia 1

    Heng-Gui Chen 1

    Fenghua Chen

    Zhi Geng

    et al.

    Open AccessPublished:May 25, 2020DOI:https://doi.org/10.1016/j.eclinm.2020.100375

    Abstract

    Background

    Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently a pandemic affecting over 200 countries. Many cities have established designated fever clinics to triage suspected COVID-19 patients from other patients with similar symptoms. However, given the limited availability of the nucleic acid test as well as long waiting time for both the test and radiographic examination, the quarantine or therapeutic decisions for a large number of mixed patients were often not made in time. We aimed to identify simple and quickly available laboratory biomarkers to facilitate effective triage at the fever clinics for sorting suspected COVID-19 patients from those with COVID-19-like symptoms.

  • 原文来源：https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30119-X/fulltext
8浏览量
原文链接
相关报告

  • 《Cell，5月10日，Validation of predictors of disease severity and outcomes in COVID-19 patients: a descriptive and retrospective study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-12
    • Validation of predictors of disease severity and outcomes in COVID-19 patients: a descriptive and retrospective study Li Tan # Xia Kang # Xinran Ji # Yongsheng Li Qiongshu Wang Hongming Miao + Published:May 10, 2020DOI:https://doi.org/10.1016/j.medj.2020.05.002 Abstract Background The severity and outcome of COVID-19 cases has been associated with percentage of circulating lymphocytes (LYM%), levels of C-reactive protein (CRP), interleukin 6 (IL-6), procalcitonin (PCT), lactic acid (LA) and viral load (ORF1ab Ct). However, the predictive power of each of these indicators in disease classification and prognosis remains largely unclear. Methods we retrospectively collected information on the above parameters in 142 patients with COVID-19, stratifying them by survival or disease severity.
    92浏览量
    原文链接

  • 《Lancet，6月24日，Tocilizumab in patients with severe COVID-19: a retrospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-26
    • Tocilizumab in patients with severe COVID-19: a retrospective cohort study Prof Giovanni Guaraldi, MD † Marianna Meschiari, MD † Prof Alessandro Cozzi-Lepri, PhD Jovana Milic, MD Roberto Tonelli, MD Marianna Menozzi, MD Published:June 24, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30173-9 Summary Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment. Methods This retrospective, observational cohort study included adults (≥18 years) with severe COVID-19 pneumonia who were admitted to tertiary care centres in Bologna and Reggio Emilia, Italy, between Feb 21 and March 24, 2020, and a tertiary care centre in Modena, Italy, between Feb 21 and April 30, 2020. All patients were treated with the standard of care (ie, supplemental oxygen, hydroxychloroquine, azithromycin, antiretrovirals, and low molecular weight heparin), and a non-randomly selected subset of patients also received tocilizumab. Tocilizumab was given either intravenously at 8 mg/kg bodyweight (up to a maximum of 800 mg) in two infusions, 12 h apart, or subcutaneously at 162 mg administered in two simultaneous doses, one in each thigh (ie, 324 mg in total), when the intravenous formulation was unavailable.
    168浏览量
    原文链接